These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 37101300)

  • 1. Efficacy of low-dose rituximab in minimal change disease and prevention of relapse.
    Zhang J; Zhao H; Li X; Qian R; Gao P; Lu S; Ma Z
    BMC Nephrol; 2023 Apr; 24(1):112. PubMed ID: 37101300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.
    Kronbichler A; König P; Busch M; Wolf G; Mayer G; Rudnicki M
    Wien Klin Wochenschr; 2013 Jun; 125(11-12):328-33. PubMed ID: 23624956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of repeat-dose rituximab maintenance therapy for minimal change disease in adults.
    Taguchi S; Ohtake T; Mochida Y; Ishioka K; Moriya H; Hidaka S; Kobayashi S
    Clin Exp Nephrol; 2020 Dec; 24(12):1132-1139. PubMed ID: 32761467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study.
    Lan L; Lin Y; Yu B; Wang Y; Pan H; Wang H; Lou X; Lang X; Zhang Q; Jin L; Yang Y; Xiao L; Chen J; Han F
    Am J Nephrol; 2024; 55(1):25-36. PubMed ID: 37963441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease.
    Papakrivopoulou E; Shendi AM; Salama AD; Khosravi M; Connolly JO; Trompeter R
    Nephrology (Carlton); 2016 Oct; 21(10):893-900. PubMed ID: 26860320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.
    Hansrivijit P; Cheungpasitporn W; Thongprayoon C; Ghahramani N
    BMC Nephrol; 2020 Apr; 21(1):134. PubMed ID: 32293308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of treatment options in adults with frequently relapsing or steroid-dependent minimal change disease.
    Heybeli C; Erickson SB; Fervenza FC; Hogan MC; Zand L; Leung N
    Nephrol Dial Transplant; 2021 Sep; 36(10):1821-1827. PubMed ID: 32918483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab in adult patients with immunosuppressive-dependent minimal change disease.
    Hoxha E; Stahl RA; Harendza S
    Clin Nephrol; 2011 Aug; 76(2):151-8. PubMed ID: 21762648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of rituximab in adult frequently relapsing minimal change disease.
    King C; Logan S; Smith SW; Hewins P
    Clin Kidney J; 2017 Feb; 10(1):16-19. PubMed ID: 28638601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective single-arm cohort study of steroid-dependent minimal change nephrotic syndrome treated with very low-dose rituximab.
    Fujimoto K; Kagaya Y; Kumano S; Fujii A; Tsuruyama Y; Matsuura T; Yamazaki K; Nomura K; Okada K; Okino K; Adachi H; Furuichi K; Yokoyama H
    Clin Nephrol; 2021 Jan; 95(1):29-36. PubMed ID: 33074094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective study.
    Ma X; Fang L; Sheng L; Zhou X; Bai S; Zang X; Wang Y; Li M; Lv Z; Zhong Q; Yang X; Wang Y; Hu Y; Yan D; Shi Y; Chen H; Li J; Tao M; Zhuang S; Wang Y; Liu N
    Ren Fail; 2023 Dec; 45(1):2237124. PubMed ID: 37482915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
    Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
    BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.
    Kronbichler A; Kerschbaum J; Fernandez-Fresnedo G; Hoxha E; Kurschat CE; Busch M; Bruchfeld A; Mayer G; Rudnicki M
    Am J Nephrol; 2014; 39(4):322-30. PubMed ID: 24751753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis.
    Lin L; Wang W; Wu Y; Xie J; Li X; Pan X; Zhang W; Xu J; Cai Y; Ren H; Chen N
    Drug Des Devel Ther; 2021; 15():1945-1953. PubMed ID: 34007154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age of Onset and Disease Course in Biopsy-Proven Minimal Change Disease: An Analysis From the Cure Glomerulonephropathy Network.
    Chen DP; Helmuth ME; Smith AR; Canetta PA; Ayoub I; Mucha K; Kallash M; Kopp JB; Gbadegesin R; Gillespie BW; Greenbaum LA; Parekh RS; Hunley TE; Sperati CJ; Selewski DT; Kidd J; Chishti A; Reidy K; Mottl AK; Gipson DS; Srivastava T; Twombley KE;
    Am J Kidney Dis; 2023 Jun; 81(6):695-706.e1. PubMed ID: 36608921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.
    Guitard J; Hebral AL; Fakhouri F; Joly D; Daugas E; Rivalan J; Guigonis V; Ducret F; Presne C; Pirson Y; Hourmant M; Glachant JC; Vendrely B; Moranne O; Faguer S; Chauveau D
    Nephrol Dial Transplant; 2014 Nov; 29(11):2084-91. PubMed ID: 24920841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING).
    C Willcocks L; Qian W; Cader R; Gatley K; Siddiqui H; Tabebisong E; Champion K; Kronbichler A; Lightstone L; Jayne D; Wilson E; Griffith M
    BMC Nephrol; 2024 Aug; 25(1):253. PubMed ID: 39112932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinico-biochemical Profile of Biopsy-proven Minimal Change Disease in Adults from a Tertiary Care Center in South India.
    Udupa KRN; Eshwarappa M; Gurudev KC; Gireesh MS; Reddy R; Yousuff M
    Saudi J Kidney Dis Transpl; 2023 May; 34(3):242-249. PubMed ID: 38231719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
    Huang J; Du J; Wang S; Xiao L; Zhao X
    Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):521-4. PubMed ID: 25224058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine.
    Fujinaga S; Hirano D; Nishizaki N; Kamei K; Ito S; Ohtomo Y; Shimizu T; Kaneko K
    Pediatr Nephrol; 2010 Mar; 25(3):539-44. PubMed ID: 20049616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.